GenMark Diagnostics : GNMK November 2020 Investor Presentation

GenMark Diagnostics

Delivering Diagnostics that Improve Patient Care

November 2020

Forward-Looking Statement

This presentation contains forward-looking statements about GenMark Diagnostics, Inc. These statements involve known and unknown risks that relate to the Company's future events or future financial performance and the actual results could differ materially from those discussed in this presentation. Factors that may cause the Company's actual results to differ materially from those discussed in the presentation, include:

• failure of the Company's products to gain market acceptance domestically or internationally;
• failure to scale our manufacturing operations to sufficiently support our anticipated future growth;
• the refusal of third-party payors to reimburse the Company's customers for use of diagnostic systems and tests;
• the loss of the Company's largest customer;
• the Company's history of net losses;
• increases in the Company's projected expenditures on sales and marketing, research and development and administrative activities;
• less than anticipated growth in the market for diagnostic testing generally and for the tests the Company is developing or may develop in the future;
• inability to obtain regulatory clearance or approval for any of the Company's products;
• changes in the regulatory environment which may adversely impact the commercialization of the Company's new products and result in significant additional capital expenditures;
• failure to enter into or maintain successful strategic alliances, which may delay the development or commercialization of the Company's products or may result in significant additional expenditures;
• failure to obtain sufficient funding for the continued development and commercialization of the Company's products;
• inability to attract or retain skilled personnel for the Company's product development and commercialization efforts; and
• inability to protect the Company's intellectual property and operate the Company's business without infringing upon the intellectual rights of others, which could result in litigation and significant expenditures.

Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of GenMark's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this presentation represent the Company's estimates and assumptions only as of the date of this presentation and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this

presentation as a result of new information, future events, or changes in the Company's expectations.

2 © Copyright 2020 GenMark Diagnostics, Inc. All rights reserved.

Recent Highlights

• 2020 revenue guidance increased from $155 - $165M to $165M - $168M
• Commercial launch of ePlex Respiratory Pathogen Panel 2 (RP2)
• Received Emergency Use Authorization (EUA) for ePlex Respiratory Pathogen Panel 2 (RP2)

Q3 Highlights:

70	115+	$6.3M	$193K
net new systems	new customers YTD	cash from operations	average annual
			annuity/placement

3 © Copyright 2020 GenMark Diagnostics, Inc. All rights reserved.

Improving Patient Care with Multiplex Molecular Diagnostics

Simple, rapid		Differentiated		Comprehensive
and actionable		ePlex® platform		Pathogen Coverage
Multiplex molecular		Highly scalable		Unique blood culture
diagnostics to help		"sample-to-answer"		ID solution and
improve management		solution with simplest		sustained leadership
of high-risk patients		workflow		in respiratory testing

$

Delivering growth + margin expansion

Proven ability to drive

revenue, improve

gross margins, generate cash

4 © Copyright 2020 GenMark Diagnostics, Inc. All rights reserved.